Back to UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

CPRXCPRX
Showing 8 of 29 quarters

Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in CATALYST PHARMACEUTICALS INC

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds 284,154 shares of CPRX (CATALYST PHARMACEUTICALS INC), worth $8.9M as of 2026-Q2. The position was increased (+1.2% shares). CPRX represents 0.0% of UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's portfolio.

Current Value

$8.9M

Current Shares

284,154

Total Value Change

+$4.2M

Total Shares Change

+47,932

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
284,154
+1.2%
$8.9M0.0%$31.43
28
2026-Q1
Increased
280,889
+0.6%
$7M0.0%$23.92
27
2025-Q4
Increased
279,281
+0.7%
$6.5M0.0%$23.29
27
2025-Q3
Decreased
277,301
-52.6%
$5.5M0.0%$19.55
0
2025-Q2
Increased
585,671
+11.3%
$12.7M0.0%$21.78
31
2025-Q1
Increased
526,297
+99.4%
$12.8M0.0%$24.69
45
2024-Q4
Increased
263,905
+11.7%
$5.5M0.0%$21.07
30
2024-Q3
Decreased
236,222
-5.9%
$4.7M0.0%$19.56
0

Other major holders of CPRX: BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used